Therapeutics of Alzheimer’s disease based on metal bioavailability

Micronutrients and Brain Health

Volumn , Issue , 2009, Pages 117-132

  Mok, Su San ^a   Bush, Ashley I ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057697897     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (183)

1. Ferri, R.T. and Levitt, P., Regulation of regional differences in the differentiation of cerebral cortical neurons by EGF family-matrix interactions. Development 121:1995.
2. Valko, M., Morris, H., and Cronin, M.T., Metals, toxicity and oxidative stress. Curr Med Chem 12:2005.
3. Tarohda, T., Yamamoto, M., and Amamo, R., Regional distribution of manganese, iron, copper, and zinc in the rat brain during development. Anal Bioanal Chem 380:2004.
4. Madaric, A., Ginter, E., and Kadrabova, J., Serum copper, zinc and copper/zinc ratio in males: Influence of aging. Physiol Res 43:1994.
5. Martinez Lista, E., et al., Changes in plasma copper and zinc during rat development. Biol Neonate, 64:1993.
6. Maynard, C.J., et al., Overexpression of Alzheimer’s disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 277:2002.
7. Ahluwalia, N., et al., Iron status and stores decline with age in Lewis rats. J Nutr 130:2000.
8. Ke, Y., et al., Age-dependent and iron-independent expression of two mRNA isoforms of divalent metal transporter 1 in rat brain. Neurobiol Aging 26:2005.
9. Ekmekcioglu, C., The role of trace elements for the health of elderly individuals. Nahrung 45:2001.
10. Iskra, M., Patelski, J., and Majewski, W., Concentrations of calcium, magnesium, zinc and copper in relation to free fatty acids and cholesterol in serum of atherosclerotic men. J Trace Elem Electrolytes Health Dis 7:1993.
11. McMaster, D., et al., Serum copper and zinc in random samples of the population of Northern Ireland. Am J Clin Nutr 56:1992.
12. Menditto, A., et al., Association of serum copper and zinc with serum electrolytes and with selected risk factors for cardiovascular disease in men aged 55-75 years. NFR Study Group. J Trace Elem Electrolytes Health Dis 7:1993.
13. Milne, D.B. and Johnson, P.E., Assessment of copper status: Effect of age and gender on reference ranges in healthy adults. Clin Chem 39:1993.
14. Prasad, A.S., et al., Zinc deficiency in elderly patients. Nutrition 9:1993.
15. Bunker, V.W., et al., Metabolic balance studies for zinc and copper in housebound elderly people and the relationship between zinc balance and leukocyte zinc concentrations. Am J Clin Nutr 46:1987.
16. Lindeman, R.D., Clark, M.L., and Colmore, J.P., Influence of age and sex on plasma and red-cell zinc concentrations. J Gerontol 26:1971.
17. Monget, A.L., et al., Micronutrient status in elderly people. Geriatrie/Min. Vit. Aux Network. Int J Vitam Nutr Res 66:1996.
18. Munro, H.N., Suter, P.M., and Russell, R.M., Nutritional requirements of the elderly. Annu Rev Nutr 7:1987.
19. Ravaglia, G., et al., Blood micronutrient and thyroid hormone concentrations in the oldest-old. J Clin Endocrinol Metab 85:2000.
20. Keen, C.L., et al., Developmental consequences of trace mineral deficiencies in rodents: Acute and longterm effects. J Nutr 133:2003.
21. Massie, H.R., Aiello, V.R., and Iodice, A.A., Changes with age in copper and superoxide dismutase levels in brains of C57BL/6J mice. Mech Ageing Dev 10:1979.
22. Morita, A., Kimura, M., and Itokawa, Y., The effect of aging on the mineral status of female mice. Biol Trace Elem Res 42:1994.
23. Takahashi, S., et al., Age-related changes in the concentrations of major and trace elements in the brain of rats and mice. Biol Trace Elem Res 80:2001.
24. Rae, T.D., et al., Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase. Science 284:1999.
25. Markesbery, W.R. and Lovell, M.A., Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol 64:2007.
26. Smith, M.A., et al., Oxidative damage in Alzheimer’s. Nature 382:1996.
27. Smith, M.A., et al., Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J Neurosci 17:1997.
28. Frederickson, C.J., Neurobiology of zinc and zinc-containing neurons. Int Rev Neurobiol 31:1989.
29. Frederickson, C.J., Koh, J.Y., and Bush, A.I., The neurobiology of zinc in health and disease. Nat Rev Neurosci 6:2005.
30. Rogers, J.T., et al., An iron-responsive element type II in the 5¢-untranslated region of the Alzheimer’s amyloid precursor protein transcript. J Biol Chem 277:2002.
31. Son, M., et al., Overexpression of CCS in G93A-SOD1 mice leads to accelerated neurological deficits with severe mitochondrial pathology. Proc Natl Acad Sci U S A 104:2007.
32. Terry, R.D., et al., Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:1991.
33. Frederickson, C.J., et al., Synaptic release of zinc from brain slices: Factors governing release, imaging, and accurate calculation of concentration. J Neurosci Methods 154:2006.
34. Danscher, G. and Stoltenberg, M., Zinc-specific autometallographic in vivo selenium methods: Tracing of zinc-enriched (ZEN) terminals, ZEN pathways, and pools of zinc ions in a multitude of other ZEN cells. J Histochem Cytochem 53:2005.
35. Schlief, M.L., Craig, A.M., and Gitlin, J.D., NMDA receptor activation mediates copper homeostasis in hippocampal neurons. J Neurosci 25:2005.
36. Schlief, M.L., et al., Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity. Proc Natl Acad Sci U S A 103:2006.
37. Uchida, Y., et al., Growth inhibitory factor prevents neurite extension and the death of cortical neurons caused by high oxygen exposure through hydroxyl radical scavenging. J Biol Chem 277:2002.
38. Uchida, Y., et al., The growth inhibitory factor that is deficient in the Alzheimer’s disease brain is a 68 amino acid metallothionein-like protein. Neuron 7:1991.
39. Lovell, M.A., et al., Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 158:1998.
40. Molina, J.A., et al., Cerebrospinal fluid levels of transition metals in patients with Alzheimer’s disease. J Neural Transm 105:1998.
41. Basun, H., et al., Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer’s disease. J Neural Transm Park Dis Dement Sect 3:1991.
42. Squitti, R., et al., Elevation of serum copper levels in Alzheimer’s disease. Neurology 59:2002.
43. Adlard, P.A. and Bush, A.I., Metals and Alzheimer’s disease. J Alzheimers Dis 10:2006.
44. Religa, D., et al., Elevated cortical zinc in Alzheimer disease. Neurology 67:2006.
45. Bartzokis, G., et al., In vivo MR evaluation of age-related increases in brain iron. AJNR Am J Neuroradiol 15:1994.
46. Hallgren, B. and Sourander, P., The effect of age on the non-haemin iron in the human brain. J Neurochem 3:1958.
47. 2 with total iron concentration in the brains of rhesus monkeys. J Magn Reson Imaging 21:2005.
48. Roskams, A.J. and Connor, J.R., Iron, transferrin, and ferritin in the rat brain during development and aging. J Neurochem 63:1994.
49. Sohal, R.S., et al., Effect of age and caloric restriction on bleomycin-chelatable and nonheme iron in different tissues of C57BL/6 mice. Free Radic Biol Med 27:1999.
50. Suh, J.H., et al., Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep 10:2005.
51. Massie, H.R., Aiello, V.R., and Williams, T.R., Iron accumulation during development and ageing of Drosophila. Mech Ageing Dev 29:1985.
52. Chinnery, P.F., et al., Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 130:2007.
53. Mantovan, M.C., et al., Exploring mental status in Friedreich’s ataxia: A combined neuropsychological, behavioral and neuroimaging study. Eur J Neurol 13:2006.
54. Zecca, L., et al., Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5:2004.
55. Castellani, R.J., et al., Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev 3:2004.
56. Moreira, P.I., et al., Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J Neural Transm 112:2005.
57. Smith, M.A., et al., Abnormal localization of iron regulatory protein in Alzheimer’s disease. Brain Res 788:1998.
58. Bishop, G.M., et al., Iron: A pathological mediator of Alzheimer disease? Dev Neurosci 24:2002.
59. Yu, W.H., et al., Metallothionein III is reduced in Alzheimer’s disease. Brain Res 894:2001.
60. Adlard, P.A., West, A.K., and Vickers, J.C., Increased density of metallothionein I/II-immunopositive cortical glial cells in the early stages of Alzheimer’s disease. Neurobiol Dis 5:1998.
61. Lovell, M.A., et al., Alterations in zinc transporter protein-1 (ZnT-1) in the brain of subjects with mild cognitive impairment, early, and late-stage Alzheimer’s disease. Neurotox Res 7:2005.
62. Melov, S., et al., Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS ONE 2:2007.
63. Bayer, T.A., et al., Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci U S A 100:2003.
64. Phinney, A.L., et al., In vivo reduction of amyloid-beta by a mutant copper transporter. Proc Natl Acad Sci U S A 100:2003.
65. Morris, M.C., et al., Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol 63:2006.
66. Sparks, D.L. and Schreurs, B.G., Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer’s disease. Proc Natl Acad Sci U S A 100:2003.
67. Sparks, D.L., et al., Trace copper levels in the drinking water, but not zinc or aluminum influence CNS Alzheimer-like pathology. J Nutr Health Aging 10:2006.
68. Stoltenberg, M., et al., Immersion autometallographic tracing of zinc ions in Alzheimer beta-amyloid plaques. Histochem Cell Biol 123:2005.
69. Yamaguchi, M., Kura, M., and Okada, S., Role of zinc as an activator of mitochondrial function in rat liver. Biochem Pharmacol 31:1982.
70. Rossi, L., et al., Mitochondrial dysfunction in neurodegenerative diseases associated with copper imbalance. Neurochem Res 29:2004.
71. Percival, S.S., Copper and immunity. Am J Clin Nutr 67:1998.
72. Wegner, M., Transcriptional control in myelinating glia: The basic recipe. Glia 29:2000.
73. Ortiz, E., et al., Effect of manipulation of iron storage, transport, or availability on myelin composition and brain iron content in three different animal models. J Neurosci Res 77:2004.
74. Hara, A. and Taketomi, T., Cerebral lipid and protein abnormalities in Menkes’ steely-hair disease. Jpn J Exp Med 56:1986.
75. Bhatnagar, S. and Taneja, S., Zinc and cognitive development. Br J Nutr 85:2001.
76. Takeda, A., Zinc homeostasis and functions of zinc in the brain. Biometals 14:2001.
77. Youdim, M.B. and Yehuda, S., The neurochemical basis of cognitive deficits induced by brain iron deficiency: Involvement of dopamine-opiate system. Cell Mol Biol (Noisy-le-grand) 46:2000.
78. Tanzi, R.E. and Bertram, L., Twenty years of the Alzheimer’s disease amyloid hypothesis: A genetic perspective. Cell 120:2005.
79. Haass, C. and Selkoe, D.J., Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8:2007.
80. Blennow, K., de Leon, M.J., and Zetterberg, H., Alzheimer’s disease. Lancet 368:2006.
81. Angeletti, B., et al., BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. J Biol Chem 280:2005.
82. Hoke, D.E., et al., In vitro gamma-secretase cleavage of the Alzheimer’s amyloid precursor protein correlates to a subset of presenilin complexes and is inhibited by zinc. FEBS J 272:2005.
83. Inestrosa, N.C., Cerpa, W., and Varela-Nallar, L., Copper brain homeostasis: Role of amyloid precursor protein and prion protein. IUBMB Life 57:2005.
84. Cerpa, W., et al., Is there a role for copper in neurodegenerative diseases? Mol Aspects Med 26:2005.
85. Atwood, C.S., et al., Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273:1998.
86. Barnham, K.J., et al., Structure of the Alzheimer’s disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J Biol Chem 278:2003.
87. Hesse, L., et al., The beta A4 amyloid precursor protein binding to copper. FEBS Lett 349:1994.
88. Simons, A., et al., Evidence for a copper-binding superfamily of the amyloid precursor protein. Biochemistry 41:2002.
89. Valensin, D., et al., Identification of a novel high affinity copper binding site in the APP(145-155) fragment of amyloid precursor protein. Dalton Trans (1): 2004.
90. Kong, G.K., et al., Copper binding to the Alzheimer’s disease amyloid precursor protein. Eur Biophys J 37:2008.
91. Bush, A.I., et al., A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer’s disease. J Biol Chem 268:1993.
92. Bush, A.I., et al., The amyloid beta-protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin-binding superfamily. J Biol Chem 269:1994.
93. Bush, A.I., et al., Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265:1994.
94. Bush, A.I., et al., Modulation of A beta adhesiveness and secretase site cleavage by zinc. J Biol Chem 269:1994.
95. Multhaup, G., et al., Interaction between the zinc (II) and the heparin binding site of the Alzheimer’s disease beta A4 amyloid precursor protein (APP). FEBS Lett 355:1994.
96. White, A.R., et al., Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res 842:1999.
97. Armendariz, A.D., et al., Gene expression profiling in chronic copper overload reveals upregulation of Prnp and App. Physiol Genomics 20:2004.
98. Bellingham, S.A., et al., Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. J Neurochem 91:2004.
99. Bellingham, S.A., et al., Copper depletion down-regulates expression of the Alzheimer’s disease amyloid-beta precursor protein gene. J Biol Chem 279:2004.
100. Borchardt, T., et al., Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. Biochem J 344:1999.
101. Cater, M.A., et al., Intracellular copper deficiency increases amyloid-beta secretion by diverse mechanisms. Biochem J 412:2008.
102. Strozyk, D., et al., Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol Aging 2007.
103. Atwood, C.S., et al., Characterization of copper interactions with Alzheimer amyloid beta peptides:Identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem 75:2000.
104. Ciuculescu, E.D., Mekmouche, Y., and Faller, P., Metal-binding properties of the peptide APP170-188:A model of the ZnII-binding site of amyloid precursor protein (APP). Chemistry 11:2005.
105. Brown, A.M., et al., Selective aggregation of endogenous beta-amyloid peptide and soluble amyloid precursor protein in cerebrospinal fluid by zinc. J Neurochem 69:1997.
106. Venti, A., et al., The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5¢-untranslated region. Ann N Y Acad Sci 1035:2004.
107. Glenner, G.G. and Wong, C.W., Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:1984.
108. Masters, C.L., et al., Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82:1985.
109. Selkoe, D.J., Amyloid beta-protein and the genetics of Alzheimer’s disease. J Biol Chem 271:1996.
110. McLean, C.A., et al., Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46:1999.
111. Hartley, D.M., et al., Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19:1999.
112. Lambert, M.P., et al., Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95:1998.
113. Lambert, M.P., et al., Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 79:2001.
114. Walsh, D.M., et al., Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274:1999.
115. Walsh, D.M., et al., Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:2002.
116. Crouch, P.J., et al., Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci 25:2005.
117. Yan, S.D., et al., An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer’s disease [see comments]. Nature 389:1997.
118. Yan, S.D., et al., Role of ERAB/l-3-hydroxyacyl-coenzyme A dehydrogenase type II activity in Abetainduced cytotoxicity. J Biol Chem 274:1999.
119. Bush, A.I., Masters, C.L., and Tanzi, R.E., Copper, beta-amyloid, and Alzheimer’s disease: Tapping a sensitive connection. Proc Natl Acad Sci U S A 100:2003.
120. Bush, A.I., The metallobiology of Alzheimer’s disease. Trends Neurosci 26:2003.
121. Cuajungco, M.P. and Faget, K.Y., Zinc takes the center stage: Its paradoxical role in Alzheimer’s disease. Brain Res Brain Res Rev 41:2003.
122. Esler, W.P., et al., Zinc-induced aggregation of human and rat beta-amyloid peptides in vitro. J Neurochem 66:1996.
123. Gaggelli, E., et al., Copper homeostasis and neurodegenerative disorders (Alzheimer’s, prion, and Parkinson’s diseases and amyotrophic lateral sclerosis). Chem Rev 106:2006.
124. Mantyh, P.W., et al., Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem 61:1993.
125. Masuoka, J. and Saltman, P., Zinc(II) and copper(II) binding to serum albumin. A comparative study of dog, bovine, and human albumin. J Biol Chem 269:1994.
126. Frederickson, C.J., et al., Concentrations of extracellular free zinc (pZn)e in the central nervous system during simple anesthetization, ischemia and reperfusion. Exp Neurol 198:2006.
127. Miller, L.M., et al., Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer’s disease. J Struct Biol 155:2006.
128. Curtain, C.C., et al., Alzheimer’s disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 276:2001.
129. Dong, J., et al., Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42:2003.
130. Behl, C., et al., Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:1994.
131. Huang, X., et al., The A beta peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38:1999.
132. Kuroda, Y. and Kawahara, M., Aggregation of amyloid beta-protein and its neurotoxicity: Enhancement by aluminum and other metals. Tohoku J Exp Med 174:1994.
133. Kanski, J., et al., Role of glycine-33 and methionine-35 in Alzheimer’s amyloid beta-peptide 1-42- associated oxidative stress and neurotoxicity. Biochim Biophys Acta 1586:2002.
134. Rottkamp, C.A., et al., Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 30:2001.
135. Smith, M.A., et al., Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 94:1997.
136. Opazo, C., et al., Metalloenzyme-like activity of Alzheimer’s disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem 277:2002.
137. Lee, J.Y., Mook-Jung, I., and Koh, J.Y., Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J Neurosci 19:1999.
138. Ha, C., Ryu, J., and Park, C.B., Metal ions differentially influence the aggregation and deposition of Alzheimer’s beta-amyloid on a solid template. Biochemistry 46:2007.
139. Moir, R.D., et al., Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. Biochemistry 38:1999.
140. Huang, X., et al., Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 274:1999.
141. Curtain, C.C., et al., Metal ions, pH, and cholesterol regulate the interactions of Alzheimer’s disease amyloid-beta peptide with membrane lipid. J Biol Chem 278:2003.
142. Abramov, A.Y., Canevari, L., and Duchen, M.R., Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci 23:2003.
143. Puglielli, L., et al., Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J Clin Invest 115:2005.
144. Ali, F.E., et al., Methionine regulates copper/hydrogen peroxide oxidation products of Abeta. J Pept Sci 11:2005.
145. Metodiewa, D., Molecular mechanisms of cellular injury produced by neurotoxic amino acids that generate reactive oxygen species. Amino Acids 14:1998.
146. Maeda, J., et al., Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer’s disease enabled by positron emission tomography. J Neurosci 27:2007.
147. Chen, K., Kazachkov, M., and Yu, P.H., Effect of aldehydes derived from oxidative deamination and oxidative stress on beta-amyloid aggregation; pathological implications to Alzheimer’s disease. J Neural Transm 114:2007.
148. Ali, F.E., et al., Dimerisation of N-acetyl-l-tyrosine ethyl ester and Abeta peptides via formation of dityrosine. Free Radic Res 40:2006.
149. Atwood, C.S., et al., Copper mediates dityrosine cross-linking of Alzheimer’s amyloid-beta. Biochemistry 43:2004.
150. Barnham, K.J., et al., Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer’s disease beta-amyloid. FASEB J 18:2004.
151. Nagano, S., et al., Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links beta-amyloid (Abeta) and generates Abeta-COX-2 hetero-oligomers that are increased in Alzheimer’s disease. J Biol Chem 279:2004.
152. Ma, Q., et al., Copper binding properties of a tau peptide associated with Alzheimer’s disease studied by CD, NMR, and MALDI-TOF MS. Peptides 27:2006.
153. Ma, Q.F., et al., Binding of copper (II) ion to an Alzheimer’s tau peptide as revealed by MALDI-TOF MS, CD, and NMR. Biopolymers 79:2005.
154. Zhou, L.X., et al., Copper (II) modulates in vitro aggregation of a tau peptide. Peptides 28:2007.
155. Sayre, L.M., et al., In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer’s disease: A central role for bound transition metals. J Neurochem 74:2000.
156. Su, X.Y., et al., Hydrogen peroxide can be generated by tau in the presence of Cu(II). Biochem Biophys Res Commun 358:2007.
157. An, W.L., et al., Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells. J Neurochem 92:2005.
158. Harris, F.M., et al., Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: Modulation by zinc. J Biol Chem, 279:2004.
159. Bjorkdahl, C., et al., Zinc induces neurofilament phosphorylation independent of p70 S6 kinase in N2a cells. NeuroReport 16:2005.
160. Danscher, G., et al., Increased amount of zinc in the hippocampus and amygdala of Alzheimer’s diseased brains: A proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. J Neurosci Methods 76:1997.
161. Opazo, C., et al., Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer’s disease. Aging Cell 5:2006.
162. Suh, S.W., et al., Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer’s diseased brains. Brain Res 852:2000.
163. Denu, J.M. and Tanner, K.G., Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: Evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 37:1998.
164. Egana, J.T., et al., Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures. Biometals 16:2003.
165. Yamamoto, A., et al., Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: Implications in the formation of neurofibrillary tangles of Alzheimer’s disease. J Neurochem 82:2002.
166. King, C.E., et al., Neuronal response to physical injury and its relationship to the pathology of Alzheimer’s disease. Clin Exp Pharmacol Physiol 27:2000.
167. d neurofilament protein binds Al, Cu and Zn. Biochem Biophys Res Commun 152:1988.
168. Crapper McLachlan, D.R., et al., Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet 337:1991.
169. Squitti, R., et al., d-penicillamine reduces serum oxidative stress in Alzheimer’s disease patients. Eur J Clin Invest 32:2002.
170. Moret, V., et al., 1,1¢-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: A new potential copper chelator agent for neuroprotection in Alzheimer’s disease. Its comparative effects with clioquinol on rat brain copper distribution. Bioorg Med Chem Lett 16:2006.
171. Lee, J.Y., et al., The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 25:2004.
172. Cherny, R.A., et al., Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 30:2001.
173. Ritchie, C.W., et al., Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot Phase 2 clinical trial. Arch Neurol 60:2003.
174. White, A.R., et al., Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent upregulation of metalloprotease activity. J Biol Chem 281:2006.
175. Kaur, D., et al., Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo:A novel therapy for Parkinson’s disease. Neuron 37:2003.
176. Nguyen, T., Hamby, A., and Massa, S.M., Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington’s disease mouse model. Proc Natl Acad Sci U S A 102:2005.
177. Adlard, P.A., et al., Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59:2008.
178. Lannfelt, L., et al., Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer’s disease: A Phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7:2008.
179. Yogev-Falach, M., et al., A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J 20:2006.
180. Avramovich-Tirosh, Y., et al., Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating-antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 4:2007.
181. Avramovich-Tirosh, Y., et al., Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer’s disease. J Neurochem 100:2007.
182. Reznichenko, L., et al., Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: Implications for iron chelation in Alzheimer’s disease. J Neurochem 97:2006.
183. Siddiq, A., et al., Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 280:2005.